Alector licensed AL050 to Genentech for a $100.0 million upfront payment and up to $1.17 billion in milestones, plus tiered royalties. The company expects current liquidity to fund operations into the second half of 2029.
ALEC · Alector, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Alector licensed AL050 globally to Genentech, receiving $100 million upfront and eligibility for up to $1.17 billion in milestones. Third-quarter net income was $124.6 million, and cash, cash equivalents and investments totaled $138.7 million at September 30, 2026.
Alector entered an underwriting agreement with Morgan Stanley & Co. LLC and BTIG, LLC for 36,600,000 shares at $2.05 per share, expecting gross proceeds of $75,030,000.00 before expenses and an October 19, 2026 close.
On October 13, 2026, Alector, Inc. repriced approximately 4.05 million employee stock options to $1.87 per share from prices of $6.48 to $33.11 per share; early exercises require the original price during a retention period.
Alector granted Genentech exclusive worldwide AL050 commercialization rights for $100 million upfront, up to $1.17 billion in milestones and tiered net-sales royalties; Alector will pay Spur $15 million, a percentage in the teens of non-royalty partnering income, and additional royalties.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALEC
this stock
Alector, Inc.
|
$347.63M | +49.7% | -79.1% | 6.7 | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 19
Alector licensed AL050 globally to Genentech, receiving $100 million upfront and eligibility for up to $1.17 billion in milestones. Third-quarter net income was $124.6 million, and cash, cash equivalents and investments totaled $138.7 million at September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALEC | -8.1% | +27.6% | +19.7% | +5.7% | +49.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.5% | +36.8% | +28.9% | +14.4% | +48.5% |